Zhengchuan Pharmapack(SH:603976)2024-04-26 12:42Financial Performance - The company's operating revenue for Q1 2024 was CNY 245,711,123.16, representing an increase of 8.94% compared to the same period last year[5]. - Net profit attributable to shareholders of the listed company reached CNY 21,047,590.27, marking a significant increase of 61.97% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 20,382,258.79, reflecting an increase of 88.37% compared to the previous year[5]. - The basic earnings per share (EPS) was CNY 0.14, which is a 55.56% increase from the same period last year[5]. - Total operating revenue for Q1 2024 reached ¥245,711,123.16, an increase of 8.5% compared to ¥225,554,847.36 in Q1 2023[16]. - Net profit for Q1 2024 was ¥21,047,590.27, representing a significant increase of 62.1% from ¥12,994,745.54 in Q1 2023[17]. - Earnings per share for Q1 2024 were ¥0.14, compared to ¥0.09 in Q1 2023, indicating a 55.6% increase[18]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,060,517,499.20, showing a slight increase of 0.86% from the end of the previous year[6]. - As of March 31, 2024, total assets amounted to RMB 2,060,517,499.20, an increase from RMB 2,042,882,148.49 as of December 31, 2023, reflecting a growth of approximately 0.86%[12]. - Current assets totaled RMB 1,082,702,774.69, up from RMB 1,051,164,929.37, indicating an increase of about 3.9%[13]. - Total liabilities decreased slightly to RMB 823,952,983.77 from RMB 827,365,223.33, a reduction of approximately 0.5%[14]. - The company's equity remained stable at RMB 1,236,564,515.43, consistent with the previous period[14]. Cash Flow - The net cash flow from operating activities was CNY 4,617,978.95, which represents a decrease of 88.23% compared to the same period last year[5]. - Cash flow from operating activities for Q1 2024 was ¥4,617,978.95, a decrease of 88.2% from ¥39,221,086.61 in Q1 2023[21]. - The net cash increase for the period was 19,872,078.32, compared to a decrease of 42,430,805.71 in the previous year[22]. - The ending balance of cash and cash equivalents was 177,123,351.40, up from 141,004,035.98 in the same period last year[22]. - The total cash outflow from financing activities was 261,440.32, compared to 540,276.01 in the previous year[22]. - The net cash flow from financing activities was -261,440.32, reflecting a decrease from -540,276.01 year-over-year[22]. Operational Insights - The increase in net profit was primarily driven by higher revenue, changes in product structure due to market demand, and tax incentives[8]. - The company reported a significant increase in net profit despite a decline in cash flow from operating activities, attributed to the increase in accounts receivable[8]. - Research and development expenses increased to ¥6,614,118.01 in Q1 2024, up from ¥4,126,878.25 in Q1 2023, marking a 60.5% rise[16]. - The company reported a total investment income of ¥409,317.55 for Q1 2024, compared to ¥264,657.53 in Q1 2023, reflecting a 54.4% increase[16]. - The company experienced a credit impairment loss of ¥4,872,708.39 in Q1 2024, worsening from a loss of ¥3,731,412.09 in Q1 2023[17]. Changes in Financial Position - Cash and cash equivalents increased to RMB 208,088,578.20 from RMB 187,621,748.94, representing a growth of approximately 10.8%[12]. - Accounts receivable rose to RMB 223,911,817.08 from RMB 152,379,478.91, marking an increase of around 47.0%[12]. - Inventory levels increased to RMB 203,320,983.13 from RMB 197,140,192.30, showing a growth of about 3.0%[13]. - The total amount of accounts payable increased to RMB 160,410,164.21 from RMB 147,604,207.25, reflecting a rise of about 8.5%[14]. - The company has no significant changes in the shareholding structure or participation in financing activities during the reporting period[12].